Dataset from A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-Infected Adults Experiencing Virological Failure

For HIV-infected individuals with highly resistant viruses, higher drug levels may be
required to block the virus. This study investigates that concept by comparing the efficacy
of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a
combination of fosamprenavir (increased dose)/lopinavir/ritonavir.